The Effects of Empagliflozin on Arterial Wall Characteristics

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT03639545

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03639545
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Slovenia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03639545. Randomized; triple masking; primary purpose treatment. Start 2018-03-01 (actual); primary completion 2018-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effects of Empagliflozin on Arterial Wall Characteristics
Condition
Vascular Stiffness
Condition
Hypoglycemic Agents
Condition
Diabetes Complications
Condition
Diabetes Mellitus, Type 1
Intervention (Drug)
Empagliflozin 25mg
Intervention (Drug)
Metformin
Intervention (Drug)
Empagliflozin/Metformin
Intervention (Drug)
Placebos
Lead sponsor
University Medical Centre Ljubljana (class: other)

Record details

Record id
cardio:ct-nct03639545
Content hash
9d018ac96bde0d2b1bb1a2c5c6dcfe2b6e33714f508622bd3bddb1415197376a